BioPorto A/S maintained its earnings guidance for the year 2022. For the year, the company expects revenue of approximately DKK 24 million to 26 million and Operating (EBIT) loss of approximately DKK 95 million to 100 million.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.23 DKK | +0.45% | +6.38% | +7.66% |
Jun. 18 | BioPorto to Raise DKK81 Million to Fund Clinical Trials | MT |
May. 30 | BioPorto A/S Appoints Niels Høy Nielsen as Member of the Executive Management Team, Effective August 1, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.66% | 140M | |
-6.51% | 12.14B | |
+96.15% | 8.43B | |
-18.38% | 6.91B | |
+9.07% | 5.93B | |
-21.66% | 3.57B | |
+5.36% | 2.53B | |
+41.54% | 2.45B | |
+17.41% | 2.94B | |
-18.43% | 1.59B |
- Stock Market
- Equities
- BIOPOR Stock
- News BioPorto A/S
- BioPorto A/S Maintains its Earnings Guidance for the Year 2022